贝美前列素对比拉坦前列素治疗青光眼有效性与安全性的Meta分析 点击下载
| 论文标题： | 贝美前列素对比拉坦前列素治疗青光眼有效性与安全性的Meta分析 |
| 英文标题： | |
| 中文摘要： | 目的 比较贝美前列素与拉坦前列素治疗青光眼的有效性和安全性，为临床合理用药提供循证参考。方法计算机检索PubMed、Embase、theCochraneLibrary、中国生物医学文献数据库、中国知网、万方数据、维普网，检索时限均为建库起至2022年3月。收集贝美前列素（试验组）对比拉坦前列素（对照组）治疗青光眼的随机对照试验（RCT），筛选文献、提取资料后，采用Co‐chrane系统评价员手册5.1.0推荐的偏倚风险评估工具对纳入文献的质量进行评价，采用RevMan5.4和Stata12软件进行Meta分析、敏感性分析和发表偏倚分析。结果共纳入19项RCT，共计2181例患者。Meta分析结果显示，试验组患者的终点眼压下降值（IOPR）[MD＝0.89，95%CI（0.53，1.25），P＜0.00001]显著低于对照组，结膜充血发生率[RR＝1.89，95%CI（1.59，2.24），P＜0.00001]、睫毛增长发生率[RR＝3.17，95%CI（1.97，5.08），P＜0.00001]均显著高于对照组；两组患者的眼睛刺激/异物感、瘙痒、眼干、眼部炎症、眼痛、视觉障碍、虹膜/皮肤色素沉着发生率比较，差异均无统计学意义（P＞0.05）。按不同用药时间节点进行的亚组分析结果显示，试验组患者用药1、3、6个月时的IOPR均显著低于对照组（P＜0.05）。敏感性分析结果显示，本研究结果稳健。发表偏倚分析结果显示，本研究存在发表偏倚的可能性较小。结论与拉坦前列素比较，贝美前列素在改善眼内压方面效果更优，但结膜充血和睫毛增长的发生风险较高。 |
| 英文摘要： | OBJECTIVE To compare the efficacy and safety of bimatoprost and latanoprost in the treatment of glaucoma， and to provide evidence-based reference for clinical rational drug use. METHODS PubMed， Embase， the Cochrane Library， China Biology Medicine disc， CNKI， Wanfang Data， and VIP databases were searched by computer to collect the randomized controlled trials （RCTs） about bimatoprost （trial group） versus latanoprost （control group） in the treatment of glaucoma from the inception to March 2022. After screening the literature and extracting the data， the qualities of the included literature were evaluated using the bias risk assessment tool recommended by the Cochrane system evaluator manual 5.1.0. Meta-analysis， sensitivity analysis and publication bias analysis were performed by using RevMan 5.4 and Stata 12 software. RESULTS A total of 2 181 patients were enrolled in 19 RCTs. Meta-analysis results showed that， the end point intraocular pressure reduction （IOPR） [MD＝0.89， 95%CI （0.53，1.25）， P＜0.000 01] of patients in trial group was significantly lower than control group， while the incidence of conjunctival congestion [RR＝1.89， 95%CI （1.59， 2.24）， P＜0.000 01] and eyelash growth [RR＝3.17， 95%CI （1.97，5.08）， P＜0.000 01] were significantly higher than control group. There was no significant difference in the incidence of eye irritation/foreign body sensation， pruritus， dry eye， eye inflammation， eye pain， visual impairment or iris/skin pigmentation between 2 groups （P＞0.05）. Results of subgroup analysis based on different medication time points showed that， the IOPR of patients in the trial group after 1， 3 and 6 months of treatment was significantly lower than control group （P＜0.05）. Results of sensitivity analysis showed that the result of this study was robust. The publication bias analysis showed that there was little possibility of publication bias in this study. CONCLUSIONS Compared with latanoprost， bimatoprost has more advantages in improving intraocular pressure， but the risk of conjunctival congestion and eyelash growth is higher than latanoprost. |
| 期刊： | 2023年第34卷第08期 |
| 作者： | 董欣宜；魏会宇；刘俊 |
| 英文作者： | DONG Xinyi，WEI Huiyu，LIU Jun |
| 关键字： | 贝美前列素；拉坦前列素；青光眼；有效性；安全性；Meta分析 |
| KEYWORDS： | bimatoprost； latanoprost； glaucoma； efficacy； safety； meta-analysis |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！